Elbasvir
| Code | Size | Price |
|---|
| AG-CR1-3729-M001 | 1 mg | £50.00 |
Quantity:
| AG-CR1-3729-M005 | 5 mg | £130.00 |
Quantity:
| AG-CR1-3729-M025 | 25 mg | £370.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
MK-8742
Appearance:
White to off-white solid.
CAS:
1370468-36-2
EClass:
32160000
Form (Short):
liquid
Handling Advice:
Keep cool and dry.
InChi:
InChI=1S/C49H55N9O7/c1-27(2)41(54-48(61)63-5)45(59)56-20-10-14-37(56)43-50-25-34(52-43)30-17-19-36-32(22-30)23-39-33-18-16-31(24-40(33)65-47(58(36)39)29-12-8-7-9-13-29)35-26-51-44(53-35)38-15-11-21-57(38)46(60)42(28(3)4)55-49(62)64-6/h7-9,12-13,16-19,22-28,37-38,41-42,47H,10-11,14-15,20-21H2,1-6H3,(H,50,52)(H,51,53)(H,54,61)(H,55,62)/t37?,38-,41-,42-,47-/m0/s1
InChiKey:
BVAZQCUMNICBAQ-ISSDNXAZSA-N
Long Description:
Chemical. CAS: 1370468-36-2. Formula: C49H55N9O7. MW: 882. Elbasvir is a direct-acting antiviral drug that potently inhibits hepatitis C virus (HCV) non-structural protein 5A (NS5A). NS5A is essential for HCV RNA synthesis and viral assembly, and elbasvir inhibits the assembly of new viral replicase complexes when used at a concentration of 50 pM. It exhibits potent inhibitory activity against a broad range of HCV genotypes. Formulations containing elbasvir have been used alone and in combination with NS3/4A protease inhibitors in the treatment of HCV. Identified as a potential inhibitor of SARS-CoV-2, responsible for COVID-19.
MDL:
MFCD28124343
Molecular Formula:
C49H55N9O7
Molecular Weight:
882
Package Type:
Vial
Product Description:
Elbasvir is a direct-acting antiviral drug that potently inhibits hepatitis C virus (HCV) non-structural protein 5A (NS5A). NS5A is essential for HCV RNA synthesis and viral assembly, and elbasvir inhibits the assembly of new viral replicase complexes when used at a concentration of 50 pM. It exhibits potent inhibitory activity against a broad range of HCV genotypes. Formulations containing elbasvir have been used alone and in combination with NS3/4A protease inhibitors in the treatment of HCV. Identified as a potential inhibitor of SARS-CoV-2, responsible for COVID-19.
Purity:
>98% (HPLC)
SMILES:
O=C(N1CCCC1C2=NC=C(C3=CC4=C(N(C5=C4)[C@@H](OC6=C5C=CC(C7=CN=C(N7)[C@@H]8CCCN8C([C@H](C(C)C)NC(OC)=O)=O)=C6)C9=CC=CC=C9)C=C3)N2)[C@@H](NC(OC)=O)C(C)C
Solubility Chemicals:
Soluble in DMSO (20mg/ml), DMF (25mg/ml) or ethanol (25mg/ml).
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Discovery of MK-8742: An HCV NS5A Inhibitor With Broad Genotype Activity: C.A. Coburn, et al.; ChemMedChem 8, 1930 (2013) | Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors: D.R. McGivern, et al.; Gastroenterology 147, 453 (2014) (Review) | Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir: R. Liu, et al.; Antimicrob. Agents Chemother. 59, 6922 (2015) | The combination of grazoprevir, a Hepatitis C virus (HCV) NS3/4A protease inhibitor, and elbasvir, an HCV NS5A inhibitor, demonstrates a high genetic barrier to resistance in HCV genotype 1a replicons: F.C. Lahser, et al.; Antimicrob. Agents Chemother. 60, 2954 (2016) | Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C: A.M. Bell, et al.; Int. J. Hepatol. 2016, 3852126 (2016) (Review) | Antiviral activity and resistance analysis of NS3/4A protease inhibitor grazoprevir and NS5A inhibitor elbasvir in Hepatitis C virus GT4 replicons: E. Asante-Appiah, et al.; Antimicrob. Agents Chemother. 61, e00363 (2017) | Fast Identification of Possible Drug Treatment of Coronavirus Disease -19 (COVID-19) Through Computational Drug Repurposing Study: J. Wang; Preprints (2020) | Computational target-based drug repurposing of elbasvir, an antiviral drug predicted to bind multiple SARS-CoV-2 proteins: M. Balasubramaniam & R.J. Shmookler Reis; ChemRxiv (Preprint) (2020)